Anticoagulants On The Survival Rate Of Patients With Idiopathic Pulmonary Arterial Hypertension Of Systematic Review And Meta-Analysis

Objective:Anticoagulation in the treatment of patients with idiopathic pulmonary arterial hypertension in whether benefit remains controversial, we aimed to assess anticoagulants impact on survival of patients with idiopathic pulmonary artery hypertension.Method:We searched for studies that evaluated anticoagulants in IPAH in the electronic databases PUBMED, WEB OF SCIENCE and COCHRANE LIBRARY and CNKI(January 2016).The intervention is Anticoagulation.The primary end point is the survival of one,two,three,five,ten years. Use revman5.3 analyze outcome events.Result:Included in article 7, a total of 1389 patients with idiopathic pulmonary arterial hypertension, in which 818 patients for anticoagulant group, the remaining 552 patients as an anticoagulant group.The end of the main indicators,1 year survival rate (OR= 1.64,95% CI (1.27,2.12],12= 25%, P= 0.0001),3 year survival rate (OR= 1.57,95% CI (1.23,2.02],12= 48%, P= 0.0003), the 5-year survival rate (OR= 2.77,95% CI (1.40,5.47],12= 0%, P= 0.003),10 years of survival rate (OR= 5.38,95% CI (1.53,18.87],12= 0%, P= 0.009), anticoagulant group were significantly better than the anticoagulation. Anticoagulant group compared with patients without anticoagulant group,2 year survival rate has no statistical significance (OR= 1.30,95% CI (0.79,2.14],12= 60%, P= 0.30).Conclusion:Short-term and long-term survival of anticoagulant group were superior to the anticoagulant group.Anticoagulant therapy is recommended for patients with idiopathic pulmonary arterial hypertension.